In this study, we not only evaluated the impact of GPR56 expression on the prognosis of ESCC patients, but also explored that the combined analysis of GPR56 expression with pathological response may have more significant predictive value for therapeutic efficacy. The gene discussed is ADGRG1; the disease is esophageal squamous cell carcinoma.